Recruitment of patients with lung cancer into a randomised clinical trial: experience at two centres. On behalf of the Big Lung Trial Steering Committee
- PMID: 10817793
- PMCID: PMC1745775
- DOI: 10.1136/thorax.55.6.463
Recruitment of patients with lung cancer into a randomised clinical trial: experience at two centres. On behalf of the Big Lung Trial Steering Committee
Abstract
Background: The entry of patients into randomised clinical trials (RCTs) in lung cancer is low. A study was undertaken to assess the reasons why patients with non-small cell lung cancer did not enter a trial involving randomisation to receive or not receive three courses of cisplatin based chemotherapy in addition to primary treatment by surgery, radiotherapy, or best supportive care.
Methods: The study was carried out in two large London institutions with a special interest in recruiting patients to lung cancer trials. Patients recently diagnosed as having non-small cell lung cancer were prospectively identified and followed to see whether they entered the RCT and, if not, to identify the main reasons why.
Results: Six hundred and eighty eight patients newly diagnosed with non-small cell lung cancer were identified between November 1995 and July 1998; 274 (39.8%) were deemed ineligible for the RCT for clinical reasons, most frequently their general condition rendering them unfit for chemotherapy. Another 161 (23.4%) were ineligible for logistical reasons-for example, they were discharged to centres not participating in the RCT or they were not considered for the trial at an appropriate time in their management. Of 253 potentially eligible patients, only 63 (24.9% of those eligible) agreed to enter the RCT and four entered another study. Of those who did not enter, 77 (41.4%) declined without stating a reason, 61 (32.8%) did not want chemotherapy, and only eight (4.3%) expressed a wish to have chemotherapy.
Conclusions: Despite considerable time and effort, the proportion of patients recruited was small (9.2%). Many seen were ineligible but, of 253 potentially eligible patients, 186 (73.5%) refused to enter the RCT.
Comment in
-
Patient accrual into chemotherapy trials in non-small cell lung cancer.Thorax. 2000 Jun;55(6):447-8. doi: 10.1136/thorax.55.6.447. Thorax. 2000. PMID: 10817789 Free PMC article. No abstract available.
Similar articles
-
Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer.Thorax. 2005 Jul;60(7):564-9. doi: 10.1136/thx.2004.039479. Thorax. 2005. PMID: 15994264 Free PMC article. Clinical Trial.
-
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.Lancet Oncol. 2012 Mar;13(3):247-55. doi: 10.1016/S1470-2045(12)70063-3. Epub 2012 Feb 16. Lancet Oncol. 2012. PMID: 22341744 Clinical Trial.
-
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.Lancet Oncol. 2015 Jul;16(7):763-74. doi: 10.1016/S1470-2045(15)00021-2. Epub 2015 Jun 1. Lancet Oncol. 2015. PMID: 26045340 Clinical Trial.
-
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.Lancet Oncol. 2014 Oct;15(11):1254-62. doi: 10.1016/S1470-2045(14)70402-4. Epub 2014 Sep 14. Lancet Oncol. 2014. PMID: 25232001 Review.
-
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.Health Technol Assess. 2015 Jun;19(47):1-134. doi: 10.3310/hta19470. Health Technol Assess. 2015. PMID: 26134145 Free PMC article. Review.
Cited by
-
Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life.Thorax. 2004 Oct;59(10):828-36. doi: 10.1136/thx.2003.020164. Thorax. 2004. PMID: 15454647 Free PMC article. Clinical Trial.
-
Telemedicine-based inspiratory muscle training and walking promotion with lung cancer survivors following curative intent therapy: a parallel-group pilot randomized trial.Support Care Cancer. 2023 Sep 1;31(9):546. doi: 10.1007/s00520-023-07999-7. Support Care Cancer. 2023. PMID: 37656252 Free PMC article. Clinical Trial.
-
Carcinoma of the bronchus 60 years later.Thorax. 2006 Dec;61(12):1023-8. doi: 10.1136/thx.2006.073106. Thorax. 2006. PMID: 17114368 Free PMC article. Review. No abstract available.
-
Treatment of acute otitis media: are children entered into clinical trials representative?Br J Gen Pract. 2001 Feb;51(463):132-3. Br J Gen Pract. 2001. PMID: 11217628 Free PMC article.
-
A randomized controlled trial of the effectiveness of a pre-recruitment primer letter to increase participation in a study of colorectal screening and surveillance.BMC Med Res Methodol. 2014 Apr 1;14:44. doi: 10.1186/1471-2288-14-44. BMC Med Res Methodol. 2014. PMID: 24690533 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical